The Miller Lab The Miller Lab The Miller Lab
  • Our Approach
  • Meet The Team
  • Publications
  • Presentations
  • Posts
  • Software
  • Funding
  • Slides
  • Donate

First Things First for Locally Advanced Cutaneous Squamous Cell Carcinoma

2026
PRIMO
CSCC
Immunotherapy
Response-guided immunotherapy in CSCC: the FIRST experience, causal reasoning, and Bayesian interpretation of treatment benefit.
Author

David M. Miller

Published

November 5, 2026

PRIMO 2026 · CUTANEOUS ONCOLOGY

First Things First

For Locally Advanced Cutaneous Squamous Cell Carcinoma

After an initial response to immunotherapy, what treatment does a patient actually need?

David M. Miller, MD, PhD

November 5, 2026

Response-guided treatment

About the talk

How much immunotherapy is enough, and which patients still need surgery or radiation? This presentation brings those practical questions into focus through the evolving treatment landscape for high-risk and locally advanced cutaneous squamous cell carcinoma (CSCC) and the Miller Lab’s institutional FIRST experience.

Frontline Immunotherapy with Response-Guided Subsequent Treatment (FIRST) provides a framework for approaching these decisions: begin with immunotherapy, reassess the response, and individualize what comes next. Subsequent management may include more immunotherapy, surgery, radiation, or close observation.

The talk moves from the clinical evidence to the challenges of interpreting an observational cohort. It introduces causal diagrams as a way to make clinical assumptions explicit and Bayesian analysis as a way to examine the probability and magnitude of potential benefit. The goal is to inform a thoughtful conversation about the least treatment needed to preserve durable disease control.

Questions explored

  • How much additional benefit might another dose of immunotherapy provide?
  • Which response findings support observation, and which call for local treatment?
  • How can causal reasoning and Bayesian analysis improve the interpretation of clinical evidence?

Presenter

David M. Miller, MD, PhD

Related research

Miller DM, Merkin RD, Kaufman HL, et al. Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation. Journal for ImmunoTherapy of Cancer. 2026;14:e015029.

Read the FIRST study Explore the analysis supplement

Presentation details

Program

PRIMO 2026

Date

Thursday, November 5, 2026

Presenter

David M. Miller, MD, PhD

Clinical focus

High-risk and locally advanced cutaneous squamous cell carcinoma

Approach

Early reassessment, response-guided treatment, and multidisciplinary decision-making

Research methods

Causal diagrams and Bayesian data analysis

This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement.